isoquercitrin

Kinisoquin (isoquercitrin) is an orally bioavailable small molecule inhibitor of protein disulfide isomerase (PDI) being developed by Quercis Pharma AG. PDI is an enzyme primarily located in the endoplasmic reticulum but is also secreted by activated endothelial cells and platelets upon vascular injury or in the presence of malignancy. Extracellular PDI is a critical mediator of thrombus formation, facilitating the activation of the coagulation cascade and platelet aggregation. By targeting PDI, Kinisoquin aims to prevent venous thromboembolism (VTE) without the significant bleeding risks associated with traditional anticoagulants like heparin or Factor Xa inhibitors. The drug is currently in Phase 3 clinical development for the prevention of VTE in patients with advanced pancreatic cancer who are starting chemotherapy, a group at exceptionally high risk for thrombotic events.

Brand names

Kinisoquin

Other names

isoquercetinquercetin-3-O-glucosidequercetin3-O-glucosidequercetin 3-O-glucosidequercetin-3-glucosidequercetin3-glucosidequercetin 3-glucoside